Technology Area: Therapeutics
276 Results for 'Therapeutics'
- Technologies (31)
- Team (0)
- News (192)
- Events (0)
- Multimedia (53)
- Publications (0)
- Jobs (0)
Technologies 31
-
OMNIVAX: Broadly Deployable Infection Vaccine Platform
Infectious diseases pose one of the greatest threats to public health, and vaccination campaigns with broad population coverage – arguably the most powerful strategy for preventing, controlling, and treating infectious diseases – have eradicated or significantly reduced the risk of contracting diseases such as smallpox, measles, polio, and tetanus. However, there is a constant need for... -
Bone Marrow-Like Scaffolds for Accelerating Immune Reconstitution
Bone marrow transplants containing hematopoietic stem cells from an immune-compatible (“allogeneic”) donor can cure patients with otherwise fatal blood disorders including multiple myeloma and leukemias by reconstituting their entire immune systems after chemotherapy. However, following such a “hematopoietic stem cell transplantation” (HSCT), the restoration of T cell immunity – which depends on the production of... -
Regenerating Tissues with Sustained Growth Factor Delivery
Millions of people worldwide suffer from traumatic injuries or health conditions that cause damage to soft tissues including nerves, muscles, and blood vessels. The body can heal some of that damage, but more serious cases like the severing of a nerve or sustained oxygen deprivation can lead to permanent loss of movement or sensation in... -
Controlled Enzymatic RNA Oligonucleotide Synthesis
Synthetic RNA oligonucleotides designed as specific successions of the four nucleobases A, U, G, and C that mimic naturally occurring RNA species are the key components of diverse RNA-based therapies. These include RNA therapeutics that can partially or completely turn off the expression of disease-causing genes (antisense and interfering RNAs), help replace or supplement dysfunctional... -
Single-Cell Encapsulation for Improved Cell Therapies
Mesenchymal stromal cells (MSCs) are valued for their ability to secrete compounds that modulate the body’s immune system, making them an attractive solution for existing problems with cell therapies including host-vs-graft disease and organ transplant rejections. However, MSCs are rapidly cleared from the body and can come under fire from the immune system. Efforts to... -
Brain Targeting Program: Shuttles for Brain Delivery of Therapeutics and Diagnostics
In its Brain Targeting Program, a Wyss team led by Founding Director Donald Ingber, M.D., Ph.D. and Staff Program Lead James Gorman, M.D., Ph.D. is developing improved approaches to target drugs and diagnostics to the brain. Leveraging the human blood-brain barrier (BBB) Chip technology developed by Ingber’s team, combined with advanced antibody R&D capabilities, the...
News 192
Multimedia 53
-
Video/AnimationOMNIVAX: Infection Vaccine PlatformThis video explains how OMNIVAX – an immuno-material-based vaccine technology can be used to rapidly create injectable vaccines against diverse viral and bacterial pathogens, and how the platform is used by the team to develop a vaccine against recurring urinary tract infections (UTIs) in their lead human application. Credit: Wyss Institute at Harvard University. -
Video/AnimationBeating Back the Coronavirus: FDA-Approved Drug Repurposing PipelineWith the goal of rapidly repurposing FDA-approved drugs to treat COVID-19, the Wyss Institute is collaborating with the Frieman Lab at the University of Maryland Medical School and the tenOever Lab at the Icahn School of Medicine at Mount Sinai to establish a multidisciplinary pipeline that can rapidly predict, test, and validate potential treatments. Credit:... -
Video/AnimationAlginate Hydrogel for AngiogenesisThis video describes how an alginate hydrogel can be used to trigger the formation of new blood vessels at an ischemic site in the body. Credit: Wyss Institute at Harvard University. -
Video/AnimationBeating Back the CoronavirusWhen the coronavirus pandemic forced Harvard University to ramp down almost all on-site operations, members of the Wyss Institute community refocused their teams, and formed new ones, in order to fight COVID-19 on its multiple fronts. These efforts include building new pieces of personal protective equipment that were delivered to frontline healthcare workers, developing new... -
Video/AnimationCogniXense: Speeding Up Treatments for Rare DiseasesAt the Wyss Institute, we are tackling Rett syndrome, a rare disease that affects 1 out of 9,000 children, by developing a scalable model for neurodevelopmental and cognitive diseases. This model can test drugs to see which will improve memory, learning, and behavior, with the end goal of finding effective therapies. Credit: Wyss Institute at... -
Video/AnimationImproving Canine HealthspanA Wyss Institute technology that can treat multiple age-related diseases is now being developed by Rejuvenate Bio into a treatment for mitral valve disease and other deadly conditions in dogs, with the goal of helping man’s best friend live longer, healthier lives. Credit: Wyss Institute at Harvard University